title: Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck.
abstract: BACKGROUND
  The purpose of this study was to evaluate the efficacy and tolerability of weekly docetaxel, cisplatin, and S-1 (weekly TPS) as induction chemotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
  
  
  METHODS
  A total of 35 patients with previously untreated, locally advanced HNSCC were enrolled. Seven patients (20%) were diagnosed with stage III HNSCC and 28 patients (80%) were diagnosed with stage IV. Induction treatment included 30 mg/m(2) docetaxel on day 1 and 8, 60 mg/m(2) cisplatin on day 1, and 70 mg/m(2) S-1 on days 1 to 14. The regimen was repeated every 21 days. After three courses of induction chemotherapy, patients received concurrent chemoradiotherapy.
  
  
  RESULTS
  Among the 35 patients, 30 (85.7%) completed induction chemotherapy. The response to induction chemotherapy was as follows: nine patients (25.7%) achieved a complete response (CR) and the overall response rate (ORR) was 85.7%. Grades 3-4 toxicity during induction therapy included neutropenia (28.5%), neutropenic fever (8.5%), and diarrhea (17.1%). After completion of concurrent chemoradiotherapy, the CR rate was 62.8% and the partial response (PR) was 22.8%. Estimates of progression-free and overall survival at 2 years were 73.2% and 79.3%, respectively.
  
  
  CONCLUSIONS
  Weekly TPS is a promising regimen that is well-tolerated, causes minimal myelosuppression and is effective as an outpatient regimen for locally advanced HNSCC.
  
  
  BACKGROUND
  ClinicalTrials.gov: NCT01645748.
authors.affiliation: Department of Hematology-Oncology, Chonnam National University, Gwangju, Korea.
authors.forename: Woo Kyun
authors.initials: WK
authors.lastname: Bae
authors.forename: Jun Eul
authors.initials: JE
authors.lastname: Hwang
authors.forename: Hyun Jeong
authors.initials: HJ
authors.lastname: Shim
authors.forename: Sang Hee
authors.initials: SH
authors.lastname: Cho
authors.forename: Ki Hyeong
authors.initials: KH
authors.lastname: Lee
authors.forename: Hye Suk
authors.initials: HS
authors.lastname: Han
authors.forename: Eun-Kee
authors.initials: EK
authors.lastname: Song
authors.forename: Hwan Jung
authors.initials: HJ
authors.lastname: Yun
authors.forename: In Sung
authors.initials: IS
authors.lastname: Cho
authors.forename: Joon Kyoo
authors.initials: JK
authors.lastname: Lee
authors.forename: Sang-Chul
authors.initials: SC
authors.lastname: Lim
authors.forename: Woong-Ki
authors.initials: WK
authors.lastname: Chung
authors.forename: Ik-Joo
authors.initials: IJ
authors.lastname: Chung
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D002945:Cisplatin